Coloplast A/S
CSE:COLO B
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
748.4
976
|
Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one COLO B stock under the Base Case scenario is 877.42 DKK. Compared to the current market price of 891.6 DKK, Coloplast A/S is Overvalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Coloplast A/S
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for COLO B cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Coloplast A/S is a leading global healthcare company headquartered in Denmark, dedicated to the development of innovative medical devices and solutions for individuals with intimate healthcare needs. Founded in 1954, the company has a strong heritage built on empathy and understanding of patient challenges, which drives its continuous commitment to enhancing the quality of life for people with chronic conditions. Coloplast operates in three primary business areas: ostomy care, urology, and continence care, crafting products that empower individuals to manage their health effectively. With a presence in over 40 countries and products sold in more than 100 markets, Coloplast not only boasts a...
Coloplast A/S is a leading global healthcare company headquartered in Denmark, dedicated to the development of innovative medical devices and solutions for individuals with intimate healthcare needs. Founded in 1954, the company has a strong heritage built on empathy and understanding of patient challenges, which drives its continuous commitment to enhancing the quality of life for people with chronic conditions. Coloplast operates in three primary business areas: ostomy care, urology, and continence care, crafting products that empower individuals to manage their health effectively. With a presence in over 40 countries and products sold in more than 100 markets, Coloplast not only boasts a robust portfolio but also demonstrates significant global reach, setting itself apart in a competitive healthcare landscape.
For investors, Coloplast presents an attractive opportunity characterized by its steady revenue growth and focus on innovation. The company has implemented a patient-centric approach, which not only fosters brand loyalty but also supports resilience in market fluctuations. With a solid track record of investing in research and development, Coloplast continually enhances its product offerings, ensuring that it remains a trusted partner for patients and healthcare providers alike. As societal trends shift towards personalized and home-based care, Coloplast's strategic initiatives aim to capitalize on these changes, making it well-positioned for sustainable growth in the long term. This strong foundation, marked by operational excellence and a commitment to corporate social responsibility, underscores Coloplast's potential to deliver both solid financial returns and positive societal impact.
Coloplast A/S is a Danish multinational company that specializes in the development and manufacturing of medical devices and products. The company primarily operates in three core business segments:
-
Chronic Care: This segment focuses on products for individuals with chronic conditions, particularly those related to ostomy care, wound care, and skin care. It includes ostomy bags, wound dressings, and products designed to protect and care for the skin. Chronic care products are critical for patients requiring long-term management of their conditions.
-
Urology: Coloplast offers a range of products that cater to urological conditions, including catheters, urine bags, and other devices for bladder management. This segment addresses the needs of patients with urinary incontinence and those who require intermittent catheterization.
-
Continence Care: This segment includes products that assist individuals suffering from incontinence issues, such as absorbent products, catheters, and related accessories. The focus is on improving the quality of life for patients who experience bladder and bowel control problems.
Coloplast emphasizes innovation and patient-centric design in all areas, ensuring that their products meet the needs of both healthcare professionals and patients. Their commitment to developing solutions that improve and simplify the lives of people with intimate healthcare needs is central to their business strategy.
Coloplast A/S, a leading company in the healthcare sector specializing in medical devices and services, possesses several unique competitive advantages that differentiate it from its rivals. Here are some key points:
-
Strong Focus on R&D and Innovation: Coloplast invests significantly in research and development. This commitment enables the company to innovate and improve its product offerings continuously, responding to the evolving needs of patients and healthcare providers.
-
Diverse Product Portfolio: Coloplast has a broad range of products across wound care, urology, ostomy care, and skin care. This diversity not only mitigates risk but also allows cross-selling opportunities and comprehensive solutions for healthcare providers.
-
Patient-Centric Approach: The company's dedication to a patient-centric approach ensures that their products are designed with the end-user in mind. This focus on user experience can lead to higher customer satisfaction and loyalty.
-
Strong Brand Reputation: With decades of experience, Coloplast has built a strong reputation for quality and reliability within the healthcare community. This reputation translates to trust among healthcare professionals and patients, providing a competitive edge.
-
Global Reach: Coloplast operates in over 40 countries, granting it significant global market access. This international footprint allows the company to benefit from diverse market segments and demographics.
-
Effective Supply Chain Management: The company has developed a robust supply chain, ensuring that products are available and can be delivered efficiently to healthcare providers and patients.
-
Regulatory Expertise: As a medical device manufacturer, Coloplast has a deep understanding of the regulatory landscape in various countries, enabling it to navigate compliance challenges effectively.
-
Sustainability Initiatives: A strong commitment to sustainability and ethical practices is becoming increasingly important to consumers. Coloplast's focus on environmentally friendly practices can serve as a differentiator in the marketplace.
-
Strategic Partnerships and Collaborations: Coloplast collaborates with various stakeholders, including healthcare providers, institutions, and patient advocacy groups, which can enhance its product development and market presence.
-
Financial Strength: Strong financial performance and management allow Coloplast to invest in growth opportunities, whether through new product development, acquisitions, or entering new markets.
By leveraging these competitive advantages, Coloplast A/S positions itself effectively in the healthcare market, enabling sustained growth and resilience against competitors.
Coloplast A/S, known for its medical devices and products related to ostomy care, continence care, and wound care, faces several risks and challenges in the near future. These may include:
-
Regulatory Challenges: The medical device industry is heavily regulated. Changes in regulations or stricter enforcement can lead to increased compliance costs and delays in product launches.
-
Market Competition: Coloplast operates in a highly competitive market. Increased competition from established players and new entrants can pressure pricing and market share.
-
Technological Advancements: Rapid changes in technology require continuous investment in research and development. Failure to innovate could lead to losing market relevance.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by geopolitical tensions or public health crises (like the COVID-19 pandemic), can impact the availability of raw materials, affecting production and delivery timelines.
-
Economic Factors: Fluctuations in global economies, including inflation and recession fears, may affect consumer spending on healthcare products and services.
-
Currency Fluctuations: As a company with international operations, Coloplast is exposed to risks from currency fluctuations which can impact revenue and profitability.
-
Reimbursement Changes: Changes in healthcare reimbursement policies or reduced healthcare budgets can affect sales, especially in markets that rely heavily on insurance.
-
Patient-Centric Trends: A shift toward patient-centric care may require Coloplast to adapt its products and services to align with changing patient preferences and behaviors.
-
Sustainability and Environmental Concerns: Rising awareness and regulations regarding sustainability and environmental impact may require Coloplast to innovate in its product lifecycle and manufacturing processes.
-
Mergers and Acquisitions: The healthcare industry is seeing consolidation. Acquisitions can present challenges like integration difficulties and cultural fit issues, which could strain resources.
-
Litigation Risks: As with many healthcare companies, Coloplast may face legal challenges related to product liability or intellectual property, which can lead to significant financial costs and reputational damage.
To navigate these challenges, Coloplast A/S will need to stay proactive in its strategic planning and operational execution, ensuring it can capitalize on opportunities while mitigating the associated risks.
Revenue & Expenses Breakdown
Coloplast A/S
Balance Sheet Decomposition
Coloplast A/S
Current Assets | 10.4B |
Cash & Short-Term Investments | 788m |
Receivables | 5.6B |
Other Current Assets | 4.1B |
Non-Current Assets | 37.6B |
Long-Term Investments | 74m |
PP&E | 6.6B |
Intangibles | 30.3B |
Other Non-Current Assets | 652m |
Current Liabilities | 10.2B |
Accounts Payable | 1.5B |
Accrued Liabilities | 7m |
Other Current Liabilities | 8.7B |
Non-Current Liabilities | 19.9B |
Long-Term Debt | 17.3B |
Other Non-Current Liabilities | 2.6B |
Earnings Waterfall
Coloplast A/S
Revenue
|
27B
DKK
|
Cost of Revenue
|
-8.8B
DKK
|
Gross Profit
|
18.3B
DKK
|
Operating Expenses
|
-11B
DKK
|
Operating Income
|
7.3B
DKK
|
Other Expenses
|
-2.2B
DKK
|
Net Income
|
5.1B
DKK
|
Free Cash Flow Analysis
Coloplast A/S
DKK | |
Free Cash Flow | DKK |
The company kicked off the year maintaining their guidance with an organic revenue growth target of around 8%. They anticipate consistent progress throughout the year across various businesses and locations, except China. While previously forecasting a revenue growth of roughly 12% in Danish kroner, currency impacts have led them to adjust the expectation to approximately 11%. The report also suggests a steady contribution from Kerecis, projecting about 4 percentage points to the overall revenue growth. The EBIT margin before special items is expected to remain between 27% to 28%.
What is Earnings Call?
COLO B Profitability Score
Profitability Due Diligence
Coloplast A/S's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Coloplast A/S's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
COLO B Solvency Score
Solvency Due Diligence
Coloplast A/S's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Coloplast A/S's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COLO B Price Targets Summary
Coloplast A/S
Dividends
Current shareholder yield for COLO B is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
Officers
The intrinsic value of one COLO B stock under the Base Case scenario is 877.42 DKK.
Compared to the current market price of 891.6 DKK, Coloplast A/S is Overvalued by 2%.